Streetbeat News

Products Services

SER

Serina Therapeutics has secured $10 million in equity financing from JuvVentures to advance its lead candidate, SER-252, into a Phase 1 clinical trial for advanced Parkinson's disease.

Portfolio Pulse from

December 02, 2024 | 10:30 pm

LOT

Lotus Technology Inc. announced its vehicle delivery results for the first eleven months of 2024, highlighting its performance as a leading global intelligent and luxury mobility provider.

Portfolio Pulse from

December 02, 2024 | 10:15 pm

BTCW

IBIT

The WisdomTree Bitcoin Fund ETF (BTCW) is facing challenges against the iShares Bitcoin Trust (IBIT) due to illiquidity and higher bid/ask spreads. BTCW offers a 0% expense ratio until 2026, but IBIT's six-month discounted fee of 0.12% attracts active traders, benefiting from better liquidity.

Portfolio Pulse from

December 02, 2024 | 10:15 pm

SBIO

The biotech sector is emerging as a potential market-beating investment opportunity. With rate cuts easing borrowing costs, tech sectors, including biotech, may benefit further from potential future cuts.

Portfolio Pulse from

December 02, 2024 | 10:00 pm

AMZN

Amazon has hired 250,000 people to manage increased holiday demand, and is using drones for deliveries in Phoenix, Arizona.

Portfolio Pulse from

December 02, 2024 | 10:00 pm

ACHR

Archer Aviation (ACHR) has experienced significant stock price volatility over the past 30 days, reflecting the turbulent nature of the emerging electric air taxi market. As of November 5th, ACHR's share price was $3.25.

Portfolio Pulse from

December 02, 2024 | 10:00 pm

RKLB

Rocket Lab's stock surged 155% in November due to new mission announcements and promising earnings results.

Portfolio Pulse from

December 02, 2024 | 9:45 pm

NCNO

nCino, Inc. (NASDAQ: NCNO) announced its participation in upcoming investor conferences, highlighting its role as a leading provider of banking solutions.

Portfolio Pulse from

December 02, 2024 | 9:45 pm

KITT

Nauticus Robotics, Inc. (NASDAQ: KITT) has successfully completed a subsea field inspection project in the Gulf of Mexico using its Aquanaut Mark 2 vehicle for a major oil and gas company.

Portfolio Pulse from

December 02, 2024 | 9:45 pm

JANX

Janux Therapeutics has announced the selection of doses for Phase 1b expansion trials of their drug JANX007, following encouraging efficacy and safety results from Phase 1a trials in metastatic castration-resistant prostate cancer (mCRPC).

Portfolio Pulse from

December 02, 2024 | 9:45 pm